Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is Biogen a Buy?

TheMotleyFool

0 0

Over the past three years, Biogen (NASDAQ: BIIB) stock has taken investors on the ride of a lifetime. Shares have consistently oscillated between over $360 a share to near $200 levels.

As it turns out, investors are heavily betting on the potential for its Alzheimer's disease therapy, aducanumab, to reach commercialization. Can Biogen successfully roll out a treatment to better help patients in a market estimated to reach nearly $5.7 billion by 2027?

Image source: Getty Images.

Source Fool.com

Like: 0

BIIB

Share